Search

Your search keyword '"Fusto, Marisa"' showing total 20 results
Start Over Author "Fusto, Marisa" Publication Year Range Last 50 years
20 results on '"Fusto, Marisa"'

1. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study

Author

Anzalone, Enza, Camici, Marta, Cannone, Fabio, Caputi, Priscilla, Cimaglia, Claudia, Corso, Rita, Cristofanelli, Flavia, Cruciani, Stefania, De Marco, Nicola, De Ponte, Chiara, Del Duca, Giulia, Faccendini, Paolo, Faraglia, Francesca, Faticoni, Augusto, Fusto, Marisa, Gebremeskel, Saba, Giancola, Maria Letizia, Giannico, Giuseppina, Gili, Simona, Iannella, Maria Rosaria, Junea, Angela, Lamonaca, Alessandra, Marani, Alessandra, Masone, Erminia, Mastrorosa, Ilaria, Mazzotta, Stefania, Nappo, Alessandra, Natalini, Giorgia, Parisi, Alfredo, Passacantilli, Sara, Paulicelli, Jessica, Plazzi, Maria Maddalena, Possi, Adriano, Preziosi, Gianni, Rosati, Silvia, Rubino, Marika, Scanzano, Pietro, Scorzolini, Laura, Tomassi, Virginia, Vescovo, Maurizio, Vita, Serena, Caterini, Luciano, Coppola, Luigi, Kontogiannis, Dimitra, D'Ettorre, Gabriella, Ridolfi, Marco, Di Giambenedetto, Simona, Farinacci, Damiano, Latini, Alessandra, Marchili, Mauro, Marocco, Raffaella, Mazzotta, Valentina, Lepri, Alessandro Cozzi, Matusali, Giulia, Cimini, Eleonora, Piselli, Pierluca, Aguglia, Camilla, Lanini, Simone, Colavita, Francesca, Notari, Stefania, Oliva, Alessandra, Meschi, Silvia, Casetti, Rita, Mondillo, Vanessa, Vergori, Alessandra, Bettini, Aurora, Grassi, Germana, Pinnetti, Carmela, Lapa, Daniele, Tartaglia, Eleonora, Gallì, Paola, Mondi, Annalisa, Montagnari, Giulia, Gagliardini, Roberta, Nicastri, Emanuele, Lichtner, Miriam, Sarmati, Loredana, Tamburrini, Enrica, Mastroianni, Claudio, Stingone, Christof, Siddu, Andrea, Barca, Alessandra, Fontana, Carla, Agrati, Chiara, Girardi, Enrico, Vaia, Francesco, Maggi, Fabrizio, and Antinori, Andrea

Published
2024
Full Text
View/download PDF

2. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

Author

Agrati, Chiara, Andreoni, Massimo, Antinori, Andrea, Bai, Francesca, Beccacece, Alessia, Barreca, Filippo, Bertuccio, Maria Paola, Bini, Teresa, Boumis, Evangelo, Camici, Marta, Cauda, Roberto, Cerva, Carlotta, Cicalini, Stefania, Cingolani, Antonella, D'Arminio Monforte, Antonella, D'Urso, Angela, De Masi, Margherita, De Zottis, Federico, Del Borgo, Cosmo, Di Gennaro, Francesco, Emiliozzi, Arianna, Fantoni, Massimo, Fondaco, Laura, Fusto, Marisa, Gagliardini, Roberta, Giovannenze, Francesca, Grilli, Elisabetta, Iannetta, Marco, Iodice, Daniele, Lichtner, Miriam, Lorenzini, Patrizia, Maffongelli, Gaetano, Masone, Erminia, Massa, Barbara, Mastrorosa, Ilaria, Mazzotta, Valentina, Mencarini, Paola, Milozzi, Eugenia, Mondi, Annalisa, Mosti, Silvia, Murri, Rita, Negri, Marcantonio, Nicastri, Emanuele, Oliva, Gian Piero, Onnelli, Giovanna, Ottou, Sandrine, Pace, Pier Giorgio, Palmieri, Fabrizio, Paulicelli, Jessica, Pinnetti, Carmela, Plazzi, Maria Maddalena, Sarmati, Loredana, Segala, Francesco Vladimiro, Sorace, Chiara, Taddei, Eleonora, Vergori, Alessandra, Vitale, Pietro, Lamonica, Silvia, Girardi, Enrico, and Vaia, Francesco

Published
2023
Full Text
View/download PDF

3. Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

Author

Ciccosanti, Fabiola, Antonioli, Manuela, Sacchi, Alessandra, Notari, Stefania, Farina, Anna, Beccacece, Alessia, Fusto, Marisa, Vergori, Alessandra, D’Offizi, Gianpiero, Taglietti, Fabrizio, Antinori, Andrea, Nicastri, Emanuele, Marchioni, Luisa, Palmieri, Fabrizio, Ippolito, Giuseppe, Piacentini, Mauro, Agrati, Chiara, and Fimia, Gian Maria

Published
2022
Full Text
View/download PDF

4. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV

Author

Vergori, Alessandra, primary, Cozzi-Lepri, Alessandro, additional, Matusali, Giulia, additional, Cicalini, Stefania, additional, Bordoni, Veronica, additional, Meschi, Silvia, additional, Mazzotta, Valentina, additional, Colavita, Francesca, additional, Fusto, Marisa, additional, Cimini, Eleonora, additional, Notari, Stefania, additional, D’Aquila, Veronica, additional, Lanini, Simone, additional, Lapa, Daniele, additional, Gagliardini, Roberta, additional, Mariotti, Davide, additional, Giannico, Giuseppina, additional, Girardi, Enrico, additional, Vaia, Francesco, additional, Agrati, Chiara, additional, Maggi, Fabrizio, additional, and Antinori, Andrea, additional

Published
2023
Full Text
View/download PDF

5. Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID‐19 booster dose in persons with HIV.

Author

Matusali, Giulia, Vergori, Alessandra, Cimini, Eleonora, Mariotti, Davide, Mazzotta, Valentina, Lepri, Alessandro Cozzi, Colavita, Francesca, Gagliardini, Roberta, Notari, Stefania, Meschi, Silvia, Fusto, Marisa, Tartaglia, Eleonora, Girardi, Enrico, Maggi, Fabrizio, and Antinori, Andrea

Subjects
BOOSTER vaccines, SARS-CoV-2 Omicron variant, COVID-19, VACCINATION status, MESSENGER RNA
Abstract

We estimated the dynamics of the neutralizing response against XBB sublineages and T cell response in persons with HIV (PWH) with previous AIDS and/or CD4 < 200/mm3 receiving the bivalent original strain/BA.4‐5 booster dose in fall 2022. Samples were collected before the shot (Day 0), 15 days, 3, and 6 months after. PWH were stratified by immunization status: hybrid immunity (HI; vaccination plus COVID‐19) versus nonhybrid immunity (nHI; vaccination only). Fifteen days after the booster, 16% and 30% of PWH were nonresponders in terms of anti‐XBB.1.16 or anti‐EG.5.1 nAbs, respectively. Three months after, a significant waning of anti‐XBB.1.16, EG.5.1 and ‐XBB.1 nAbs was observed both in HI and nHI but nAbs in HI were higher than in nHI. Six months after both HI and nHI individuals displayed low mean levels of anti‐XBB.1.16 and EG.5.1 nAbs. Regarding T cell response, IFN‐γ values were stable over time and similar in HI and nHI. Our data showed that in PWH, during the prevalent circulation of the XBB.1.16, EG.5.1, and other XBB sublineages, a mRNA bivalent vaccine might not confer broad protection against them. With a view to the 2023/2024 vaccination campaign, the use of the monovalent XBB.1.5 mRNA vaccine should be urgently warranted in PWH to provide adequate protection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in PLWH

Author

Vergori, Alessandra, primary, Cozzi-Lepri, Alessandro, additional, Matusali, Giulia, additional, Cicalini, Stefania, additional, Bordoni, Veronica, additional, Meschi, Silvia, additional, Mazzotta, Valentina, additional, Colavita, Francesca, additional, Fusto, Marisa, additional, Cimini, Eleonora, additional, Notari, Stefania, additional, D'Aquila, Veronica, additional, Lanini, Simone, additional, Lapa, Daniele, additional, Gagliardini, Roberta, additional, Mariotti, Davide, additional, Giannico, Giuseppina, additional, Girardi, Enrico, additional, Vaia, Francesco, additional, Agrati, Chiara, additional, Maggi, Fabrizio, additional, and Antinori, Andrea, additional

Published
2023
Full Text
View/download PDF

7. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV

Author

Vergori, Alessandra, primary, Matusali, Giulia, additional, Lepri, Alessandro Cozzi, additional, Cimini, Eleonora, additional, Fusto, Marisa, additional, Colavita, Francesca, additional, Gagliardini, Roberta, additional, Notari, Stefania, additional, Mazzotta, Valentina, additional, Mariotti, Davide, additional, Cicalini, Stefania, additional, Girardi, Enrico, additional, Vaia, Francesco, additional, Maggi, Fabrizio, additional, and Antinori, Andrea, additional

Published
2023
Full Text
View/download PDF

8. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

Author

Mastrorosa, Ilaria, primary, Gagliardini, Roberta, additional, Segala, Francesco Vladimiro, additional, Mondi, Annalisa, additional, Lorenzini, Patrizia, additional, Cerva, Carlotta, additional, Taddei, Eleonora, additional, Bai, Francesca, additional, Vergori, Alessandra, additional, Negri, Marcantonio, additional, Pinnetti, Carmela, additional, Cicalini, Stefania, additional, Murri, Rita, additional, Mazzotta, Valentina, additional, Camici, Marta, additional, Mosti, Silvia, additional, Bini, Teresa, additional, Maffongelli, Gaetano, additional, Beccacece, Alessia, additional, Milozzi, Eugenia, additional, Iannetta, Marco, additional, Lamonica, Silvia, additional, Fusto, Marisa, additional, Plazzi, Maria Maddalena, additional, Ottou, Sandrine, additional, Lichtner, Miriam, additional, Fantoni, Massimo, additional, Andreoni, Massimo, additional, Sarmati, Loredana, additional, Cauda, Roberto, additional, Girardi, Enrico, additional, Nicastri, Emanuele, additional, D'Arminio Monforte, Antonella, additional, Palmieri, Fabrizio, additional, Cingolani, Antonella, additional, Vaia, Francesco, additional, Antinori, Andrea, additional, Agrati, Chiara, additional, Barreca, Filippo, additional, Bertuccio, Maria Paola, additional, Boumis, Evangelo, additional, D'Urso, Angela, additional, De Masi, Margherita, additional, De Zottis, Federico, additional, Del Borgo, Cosmo, additional, Di Gennaro, Francesco, additional, Emiliozzi, Arianna, additional, Fondaco, Laura, additional, Giovannenze, Francesca, additional, Grilli, Elisabetta, additional, Iodice, Daniele, additional, Masone, Erminia, additional, Massa, Barbara, additional, Mastrorosa, Ilaria, additional, Mencarini, Paola, additional, Oliva, Gian Piero, additional, Onnelli, Giovanna, additional, Pace, Pier Giorgio, additional, Paulicelli, Jessica, additional, Sorace, Chiara, additional, and Vitale, Pietro, additional

Published
2023
Full Text
View/download PDF

9. Declining Prevalence of Human Immunodeficiency Virus (HIV)–Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy–Treated Individuals With HIV

Author

Mastrorosa, Ilaria, primary, Pinnetti, Carmela, additional, Brita, Anna Clelia, additional, Mondi, Annalisa, additional, Lorenzini, Patrizia, additional, Del Duca, Giulia, additional, Vergori, Alessandra, additional, Mazzotta, Valentina, additional, Gagliardini, Roberta, additional, Camici, Marta, additional, De Zottis, Federico, additional, Fusto, Marisa, additional, Plazzi, Maria Maddalena, additional, Grilli, Elisabetta, additional, Bellagamba, Rita, additional, Cicalini, Stefania, additional, and Antinori, Andrea, additional

Published
2022
Full Text
View/download PDF

10. SARS-CoV-2 Omicron Variant Neutralization after Third Dose Vaccination in PLWH

Author

Vergori, Alessandra, primary, Cozzi-Lepri, Alessandro, additional, Matusali, Giulia, additional, Colavita, Francesca, additional, Cicalini, Stefania, additional, Gallì, Paola, additional, Garbuglia, Anna Rosa, additional, Fusto, Marisa, additional, Puro, Vincenzo, additional, Maggi, Fabrizio, additional, Girardi, Enrico, additional, Vaia, Francesco, additional, and Antinori, Andrea, additional

Published
2022
Full Text
View/download PDF

11. Declining Prevalence of Human Immunodeficiency Virus (HIV)–Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy–Treated Individuals With HIV.

Author

Mastrorosa, Ilaria, Pinnetti, Carmela, Brita, Anna Clelia, Mondi, Annalisa, Lorenzini, Patrizia, Duca, Giulia Del, Vergori, Alessandra, Mazzotta, Valentina, Gagliardini, Roberta, Camici, Marta, Zottis, Federico De, Fusto, Marisa, Plazzi, Maria Maddalena, Grilli, Elisabetta, Bellagamba, Rita, Cicalini, Stefania, and Antinori, Andrea

Subjects
HIV infection epidemiology, HIV infection complications, MENTAL illness drug therapy, HIV infections, COGNITION disorders, AIDS dementia complex, HIV integrase inhibitors, CROSS-sectional method, MULTIVARIATE analysis, MULTIPLE regression analysis, AGE distribution, ANTIRETROVIRAL agents, TREATMENT effectiveness, CHI-squared test, DISEASE prevalence, NON-nucleoside reverse transcriptase inhibitors, RESEARCH funding, EDUCATIONAL attainment, EVALUATION
Abstract

Background HIV-associated neurocognitive disorders (HAND) have been suggested as persistent even with effective antiretroviral therapy (ART). Aims were to evaluate HAND prevalence and associated factors, in a large cohort of people-with-HIV (PWH). Methods ART-treated PWH, underwent a neuropsychological examination through a battery of 12 tests exploring 5 different domains, between 2009 and 2020, were included in this cross-sectional analysis. HAND were classified according to Frascati's criteria. Participants were defined as complaining or not-complaining if a cognitive complaint was reported or not. Chi-square for trend and multivariable logistic regression were fitted. Results Overall, 1424 PWH were enrolled during four three-years periods. HAND prevalence was 24%; among complainers (572/1424), it was 38%, higher than among not-complainers (15%). Over the study period, a decreasing HAND prevalence was found in the entire population (P < 0.001) and in complaining (P < 0.001); in not-complaining it remained stable (P = 0.182). Factors associated with HAND were older age, lower educational level, lower current CD4+ T-cell count and HCV co-infection. Compared to nonnucleoside reverse transcriptase inhibitors, receiving dual and integrase strand transfer inhibitor (INSTI)-based therapies was associated with a decreased risk of HAND, as well as being tested in more recent years. Conclusions In this large cohort of ART-treated PWH, mostly virologically suppressed, a remarkable decreasing HAND prevalence was observed. Besides HIV- and patient-related factors, the reduced risk of HAND found with dual and INSTI-based regimens along with a more recent ART initiation, could suggest a potential role of new treatment strategies in this decline, due to their greater virologic efficacy and better tolerability. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH

Author

Gagliardini, Roberta, primary, Vergori, Alessandra, additional, Lorenzini, Patrizia, additional, Cicalini, Stefania, additional, Pinnetti, Carmela, additional, Mazzotta, Valentina, additional, Mondi, Annalisa, additional, Mastrorosa, Ilaria, additional, Camici, Marta, additional, Lanini, Simone, additional, Fusto, Marisa, additional, Paulicelli, Jessica, additional, Plazzi, Maria Maddalena, additional, Marchioni, Luisa, additional, Agrati, Chiara, additional, Garbuglia, Anna Rosa, additional, Piselli, Pierluca, additional, Nicastri, Emanuele, additional, Taglietti, Fabrizio, additional, Palmieri, Fabrizio, additional, D’Offizi, Gianpiero, additional, Girardi, Enrico, additional, Vaia, Francesco, additional, and Antinori, Andrea, additional

Published
2022
Full Text
View/download PDF

13. Additional file 1 of Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

Author

Ciccosanti, Fabiola, Antonioli, Manuela, Sacchi, Alessandra, Notari, Stefania, Farina, Anna, Beccacece, Alessia, Fusto, Marisa, Vergori, Alessandra, D’Offizi, Gianpiero, Taglietti, Fabrizio, Antinori, Andrea, Nicastri, Emanuele, Marchioni, Luisa, Palmieri, Fabrizio, Ippolito, Giuseppe, Piacentini, Mauro, Agrati, Chiara, and Fimia, Gian Maria

Abstract

Additional file 1: Tables S1: Demographics, clinical baseline characteristics, therapy and cause of death of COVID-19 patients.

Published
2022
Full Text
View/download PDF

14. Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

Author

Mastrorosa, Ilaria, primary, Gagliardini, Roberta, additional, Segala, Francesco, additional, Mondi, Annalisa, additional, Lorenzini, Patrizia, additional, Cerva, Carlotta, additional, Taddei, Eleonora, additional, Bai, Francesca, additional, Vergori, Alessandra, additional, Marcantonio, Negri, additional, Pinnetti, Carmela, additional, Cicalini, Stefania, additional, Murri, Rita, additional, Mazzotta, Valentina, additional, Camici, Marta, additional, Mosti, Silvia, additional, Bini, Teresa, additional, Maffongelli, Gaetano, additional, Beccacece, Alessia, additional, Milozzi, Eugenia, additional, Iannetta, Marco, additional, Lamonica, Silvia, additional, Fusto, Marisa, additional, Plazzi, Maria Maddalena, additional, Ottou, Sandrine, additional, Lichtner, Miriam, additional, Fantoni, Massimo, additional, Andreoni, Massimo, additional, Sarmati, Loredana, additional, Cauda, Roberto, additional, Girardi, Enrico, additional, Nicastri, Emanuele, additional, D'Arminio Monforte, Antonella, additional, Palmieri, Fabrizio, additional, Cingolani, Antonella, additional, Vaia, Francesco, additional, Antinori, Andrea, additional, and Group, ESCAPE Study, additional

Published
2022
Full Text
View/download PDF

15. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count

Author

Antinori, Andrea, primary, Cicalini, Stefania, additional, Meschi, Silvia, additional, Bordoni, Veronica, additional, Lorenzini, Patrizia, additional, Vergori, Alessandra, additional, Lanini, Simone, additional, De Pascale, Lidya, additional, Matusali, Giulia, additional, Mariotti, Davide, additional, Lepri, Alessandro Cozzi, additional, Gallì, Paola, additional, Pinnetti, Carmela, additional, Gagliardini, Roberta, additional, Mazzotta, Valentina, additional, Mastrorosa, Ilaria, additional, Grisetti, Susanna, additional, Colavita, Francesca, additional, Cimini, Eleonora, additional, Grilli, Elisabetta, additional, Bellagamba, Rita, additional, Lapa, Daniele, additional, Sacchi, Alessandra, additional, Marani, Alessandra, additional, Cerini, Carlo, additional, Candela, Caterina, additional, Fusto, Marisa, additional, Puro, Vincenzo, additional, Castilletti, Concetta, additional, Agrati, Chiara, additional, Girardi, Enrico, additional, Vaia, Francesco, additional, and Group, HIV-VAC Study, additional

Published
2021
Full Text
View/download PDF

16. Identification of a novel chalcone derivative that inhibits Notch signaling in T-cell acute lymphoblastic leukemia

Author

Mori, Mattia, primary, Tottone, Luca, additional, Quaglio, Deborah, additional, Zhdanovskaya, Nadezda, additional, Ingallina, Cinzia, additional, Fusto, Marisa, additional, Ghirga, Francesca, additional, Peruzzi, Giovanna, additional, Crestoni, Maria Elisa, additional, Simeoni, Fabrizio, additional, Giulimondi, Francesca, additional, Talora, Claudio, additional, Botta, Bruno, additional, Screpanti, Isabella, additional, and Palermo, Rocco, additional

Published
2017
Full Text
View/download PDF

18. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count

Author

Andrea, Antinori, Stefania, Cicalini, Silvia, Meschi, Veronica, Bordoni, Patrizia, Lorenzini, Alessandra, Vergori, Simone, Lanini, Lidya, De Pascale, Giulia, Matusali, Davide, Mariotti, Alessandro, Cozzi Lepri, Paola, Gallì, Carmela, Pinnetti, Roberta, Gagliardini, Valentina, Mazzotta, Ilaria, Mastrorosa, Susanna, Grisetti, Francesca, Colavita, Eleonora, Cimini, Elisabetta, Grilli, Rita, Bellagamba, Daniele, Lapa, Alessandra, Sacchi, Alessandra, Marani, Carlo, Cerini, Caterina, Candela, Marisa, Fusto, Vincenzo, Puro, Concetta, Castilletti, Chiara, Agrati, Enrico, Girardi, Francesco, Vaia, Antinori, Andrea, Cicalini, Stefania, Meschi, Silvia, Bordoni, Veronica, Lorenzini, Patrizia, Vergori, Alessandra, Lanini, Simone, De Pascale, Lidya, Matusali, Giulia, Mariotti, Davide, Cozzi Lepri, Alessandro, Gallì, Paola, Pinnetti, Carmela, Gagliardini, Roberta, Mazzotta, Valentina, Mastrorosa, Ilaria, Grisetti, Susanna, Colavita, Francesca, Cimini, Eleonora, Grilli, Elisabetta, Bellagamba, Rita, Lapa, Daniele, Sacchi, Alessandra, Marani, Alessandra, Cerini, Carlo, Candela, Caterina, Fusto, Marisa, Puro, Vincenzo, Castilletti, Concetta, Agrati, Chiara, Girardi, Enrico, and Vaia, Francesco

Subjects
Microbiology (medical), CD4-Positive T-Lymphocytes, COVID-19 Vaccines, CoV, COVID-19 Vaccine, HIV Infections, immunogenicity, Antibodies, Viral, anti, Humans, HIV Infection, Lymphocyte Count, Prospective Studies, RNA, Messenger, BNT162 Vaccine, SARS, Immunity, Cellular, 2 vaccine, SARS-CoV-2, Vaccination, COVID-19, HIV, Viral Vaccines, AIDS, Prospective Studie, Infectious Diseases, CD4-Positive T-Lymphocyte, Immunoglobulin G, Human
Abstract

Background Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count Methods PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: 500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used Findings Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell Conclusion Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell 500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200–500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population

Published
2021

19. Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition.

Author

Vergori A, Del Duca G, Lorenzini P, Brita AC, Mastrorosa I, Fusto M, Camici M, Ottou S, Gagliardini R, Paulicelli J, De Zottis F, Grilli E, Esvan R, Plazzi MM, Mazzotta V, Bellagamba R, Antinori A, and Pinnetti C

Abstract

Objectives: The aim was to investigate whether switching from EFV/F/TDF to B/F/TAF may improve neuropsychiatrc symptoms and neurocognition., Design: Pilot, single-arm, prospective study of persons with HIV (PWH) on the efficacy and safety of switching from EFV/F/TDF to B/F/TAF., Methods: Participants underwent neuropsychological assessment (NPA) at switch (T0) and after 48 weeks (T1). NPA was carried out through a standardized battery of 12 tests. Neurocognitive impairment (NCI) was defined by a score ≥1 standard deviation (SD) below the normal mean on at least 2 tests or ≥2 SD below on 1 test. Individual z-scores were determined, NPZ-12 was calculated as the average of 12 test z-scores and change of NPZ-12 was the outcome. HIV-associated Neurocognitive Disorder (HAND) was classified by Frascati's criteria. Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and Pittsburgh Sleep Quality Index (PSQI) were administered. Paired-Wilcoxon and McNemar tests were used for comparisons, and logistic regression for associations with NCI changes., Results: Out of 126 participants, BAI, BDI-II, and PSQI questionnaires revealed an improvement at T1. NPA revealed NCI in 40.5% of persons at T0 and 42.1% at T1 (p = 0.746). Specifically, at T0, among participants with NCI, 35% improved; among those without, 26% worsened at T1; NPZ-12 score worsened at T1. 5.6% of ANI was observed at T0 and 7.9% at T1. No factor associated with these changes was found., Conclusions: Our results suggest switching from EFV/F/TDF to B/F/TAF significantly improves psychiatric symptoms and sleep quality. Neurocognitive performance remained stable, although a decline in NPZ-12 and in specific domains was observed., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

20. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.

Author

Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De Pascale L, Matusali G, Mariotti D, Cozzi Lepri A, Gallì P, Pinnetti C, Gagliardini R, Mazzotta V, Mastrorosa I, Grisetti S, Colavita F, Cimini E, Grilli E, Bellagamba R, Lapa D, Sacchi A, Marani A, Cerini C, Candela C, Fusto M, Puro V, Castilletti C, Agrati C, Girardi E, and Vaia F

Subjects
Antibodies, Viral, BNT162 Vaccine, CD4-Positive T-Lymphocytes, COVID-19 Vaccines, HIV, Humans, Immunity, Cellular, Immunoglobulin G, Lymphocyte Count, Prospective Studies, RNA, Messenger, SARS-CoV-2, Vaccination, COVID-19 prevention & control, HIV Infections drug therapy, Viral Vaccines
Abstract

Background: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count., Methods: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm3; intermediate CD4 recovery, ICDR: 200-500/mm3; high CD4 recovery, HCDR: >500/mm3). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used., Findings: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters., Conclusion: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm3 versus those with >500 cell/mm3 and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200-500/mm3, whereas immune response elicited in PLWH with a CD4 T-cell >500/mm3 was comparable to HIV-negative population., (© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results